Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi therapeutic Amvuttra.The EC has now approved Amvuttra for the treatment of ...

Alnylam Pharmaceuticals (Nasdaq: ALNY) has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

See the latest Alnylam Pharmaceuticals Inc stock price (ALNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

For payers, claims for rare disease treatments used to be uncommon. Not anymore, thanks to an increasing number of new, ...

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...

Analysts have set 12-month price targets for Alnylam Pharmaceuticals, revealing an average target of $352.22, a high estimate of $500.00, and a low estimate of $268.00.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to ...

Review the current Alnylam Pharmaceuticals Inc (ALNY:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if ALNY is the best investment for you.

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic porphyria (AHP). A recently released patient storytelling initiative by the ...